Integrating AI and ADME Tools to Refine Early-Stage Drug Discovery
Drug discovery teams frequently face late-stage trial surprises due to a lack of human pharmacokinetic insight during the initial development phases. A new webinar aims to address this gap by demonstrating how integrated, AI-driven ADME workflows can refine compound prioritization and significantly reduce inefficient synthesis cycles.
The upcoming session, hosted by Xtalks, focuses on shifting human pharmacokinetic (PK) projection into the earliest stages of the discovery funnel. By utilizing a complete Tier 1 ADME panel combined with automated data generation, researchers can turn individual assay results into actionable endpoints. This approach is designed to support full-series evaluation, allowing teams to identify promising compounds before committing to costly synthesis cycles.
Experts Jonathan Grob from Ginkgo Bioworks, Alex Taylor of Inductive Bio, and Tangible Scientific co-founder Ted Peters will lead the presentation. They will examine how moving lead-optimization-quality data into the hit identification phase improves overall decision-making. The live broadcast is scheduled for Thursday, July 30, 2026, at 12pm EDT, providing a platform for discovery teams to learn how these novel tools can increase the likelihood of success in human trials.
Comments (0)
No comments yet. Be the first!